Entos Pharmaceuticals
PrivateLast Round
Grant
Aug 1, 2025
Total Funding Raised
$126.85M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Entos Pharmaceuticals is a biotechnology company developing genetic medicines using its proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Entos Pharmaceuticals Comparables
Compare Entos Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NanoVation Therapeutics | 89% | |
| Acuitas Therapeutics | 87% | |
| Genevant Sciences | 87% |
Entos Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 1, 2025 | ||||
| VC Round | May 22, 2025 | ||||
| Grant | Mar 11, 2025 | ||||
| Grant | Feb 5, 2025 | ||||
| Grant | Oct 7, 2023 | ||||
Grant | Oct 1, 2022 |
Entos Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Canadian Institutes of Health Research | Grant |
| Canadian International Innovation Program | Grant |
| CureDuchenne Ventures | VC Round |
| National Research Council Canada Industrial Research Assistance Program | Grant |
| National Research Council Canada | Grant |
| Government of Canada | Grant |
| California Institute for Regenerative Medicine | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 32% MoM.
- Apr 20, 2026
Developing a curative therapy for LMNA-Related Congenital Muscular Dystrophy.
Entos Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Entos Pharmaceuticals's valuation, stock price, and market status.
Is Entos Pharmaceuticals a public or private company?
Entos Pharmaceuticals is a private company.
What is the current stock price of Entos Pharmaceuticals?
Entos Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.
How much is Entos Pharmaceuticals worth (valuation)?
Valuation information for Entos Pharmaceuticals is not publicly available.
Can I buy Entos Pharmaceuticals stock?
Entos Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Entos Pharmaceuticals's last funding round?
Entos Pharmaceuticals's most recent funding round was Grant on August 1, 2025.
Who are the main investors in Entos Pharmaceuticals?
Key investors in Entos Pharmaceuticals include CureDuchenne Ventures.
Will Entos Pharmaceuticals IPO soon?
No public IPO plans have been announced for Entos Pharmaceuticals.
How can I track Entos Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Entos Pharmaceuticals's secondary market activity and sign up for updates.